# Absci Tells Guggenheim Conference Its Lead Antibody ABS-201 Is Now in Phase 2

> Absci's Alexander Khan told Guggenheim's healthcare conference that lead antibody ABS-201 is in Phase 2.

- Published: 2026-11-11T22:51:43+00:00
- Section: Business
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-11/absci-abs-201-phase-2-guggenheim
- Source: [Seeking Alpha](https://seekingalpha.com/article/4966691-absci-corporation-absi-presents-at-3rd-annual-guggenheim-healthcare-innovation-conference?source=feed_all_articles)

## Key takeaways

- Absci's lead antibody program ABS-201 is in Phase 2, Alexander Khan said at the 3rd Annual Guggenheim Healthcare Innovation Conference.
- Khan described Absci's shift from an AI drug creation platform working with pharma partners to a company that owns its own antibody pipeline.
- Absci closed a $100 million underwritten stock offering in June 2026, with Eli Lilly investing $40 million as lead.

[Absci](https://akta.pro/company-profiles/00000tg/absci)'s lead antibody program ABS-201 is in Phase 2, the company's head of investor relations told the 3rd Annual Guggenheim Healthcare Innovation Conference on November 10, 2026. Alexander Khan, corporate vice president for finance and investor relations, presented at the event, [Seeking Alpha](https://seekingalpha.com/article/4966691-absci-corporation-absi-presents-at-3rd-annual-guggenheim-healthcare-innovation-conference?source=feed_all_articles) reported. Absci is a publicly traded generative AI drug creation company that designs and validates biologic drug candidates.

## Khan Describes Absci's Shift to Owning Its Pipeline

Khan told the conference that Absci has moved from an AI drug creation platform working with a number of pharma partners to a pipeline-owning company building its own antibody programs. "Right now, our lead program, ABS-201, is in a Phase," Khan said, according to the transcript. Guggenheim analyst Vamil Divan opened the session by noting that a lot had changed at Absci over the previous 12 months, and asked Khan for background on the company's story and key developments before moving to questions. Arseniy Shabashvili, another member of the Guggenheim team, joined Divan on stage.

## The June 2026 Offering and Phase 1 Data

According to akta.pro [company records](https://akta.pro/company-data), Absci closed a $100 million underwritten stock offering in June 2026, with Eli Lilly investing $40 million as lead alongside Adage, BVF Partners, Columbia Threadneedle, Invus and Redmile. The offering was announced concurrently with positive interim Phase 1 data from the HEADLINE trial of ABS-201, an anti-PRLR antibody for androgenetic alopecia. Those data showed no serious adverse events in 32 healthy adults and an estimated half-life of 65+ days supporting two to three doses over six months. The same records list total funding of $494.3 million, with the last round dated June 24, 2026.

## Earlier Steps Toward the ABS-201 Program

Absci outlined a global Phase 2 trial for ABS-201 targeting endometriosis and alopecia, Simply Wall St reported in September 2026. In October 2026, AMD reported that Absci's antibody-design workflow ran three times faster on Instinct GPUs using ROCm and optimized Triton kernels while maintaining output quality, Blockchain News reported. Absci also said it would take part in three investor conferences, with fireside chats on November 10, November 18 and December 1, 2026, in Boston, London and Coral Gables, Stock Titan reported.

## ABS-201 Data Expected in December

Absci is scheduled to report third-quarter earnings, and ABS-201 hair-loss trial data are expected in December, Investing.com reported. The company's fireside chats are set for November 18 and December 1, 2026.

## Companies in this story

- [Absci company profile](https://akta.pro/company-profiles/00000tg/absci) · website: https://www.absci.com

---
News for Agent · https://newsforagent.com/llms.txt